Verrica Pharma Changes HQ Address in West Chester, PA

Ticker: VRCA · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1660334

Verrica Pharmaceuticals Inc. 8-K Filing Summary
FieldDetail
CompanyVerrica Pharmaceuticals Inc. (VRCA)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: administrative-change, corporate-update

TL;DR

**Verrica Pharma moved its office, no big deal for the stock.**

AI Summary

Verrica Pharmaceuticals Inc. filed an 8-K on January 8, 2024, to report a change in its principal executive offices from 10 North High Street, Suite 200, West Chester, PA 19380 to 44 W. Gay St., Suite 400, West Chester, PA 19380. This administrative update signals a minor operational adjustment for the company. For investors, this change is largely inconsequential, as it doesn't impact the company's financial health, product pipeline, or strategic direction, but rather reflects a routine business relocation.

Why It Matters

This filing indicates a minor administrative change for Verrica Pharmaceuticals, specifically a new office address, which has no direct impact on the company's financial performance or stock value.

Risk Assessment

Risk Level: low — The filing reports a routine administrative change (office address) with no material impact on the company's operations or financial standing.

Analyst Insight

Investors should note this administrative update but recognize it has no material impact on Verrica Pharmaceuticals' business operations or financial outlook, thus requiring no immediate investment action.

Key Players & Entities

  • Verrica Pharmaceuticals Inc. (company) — the registrant filing the 8-K
  • January 8, 2024 (date) — date of earliest event reported and filing date
  • 10 North High Street, Suite 200, West Chester, PA 19380 (address) — Verrica Pharmaceuticals' previous principal executive office address
  • 44 W. Gay St., Suite 400, West Chester, PA 19380 (address) — Verrica Pharmaceuticals' new principal executive office address
  • VRCA (ticker) — trading symbol for Verrica Pharmaceuticals Inc.
  • The Nasdaq Stock Market LLC (exchange) — exchange where Verrica Pharmaceuticals' Common Stock is registered

FAQ

What is the primary purpose of this 8-K filing by Verrica Pharmaceuticals Inc.?

The primary purpose of this 8-K filing is to report a change in the principal executive offices of Verrica Pharmaceuticals Inc., effective January 8, 2024.

What was Verrica Pharmaceuticals Inc.'s previous principal executive office address?

Verrica Pharmaceuticals Inc.'s previous principal executive office address was 10 North High Street, Suite 200, West Chester, PA 19380.

What is Verrica Pharmaceuticals Inc.'s new principal executive office address as reported in this filing?

Verrica Pharmaceuticals Inc.'s new principal executive office address is 44 W. Gay St., Suite 400, West Chester, PA 19380.

On what date was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 8, 2024.

Is Verrica Pharmaceuticals Inc. considered an emerging growth company according to this filing?

Yes, the filing indicates with a checkmark that Verrica Pharmaceuticals Inc. is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-01-08 08:01:10

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On January 8, 2024, Verrica Pharmaceuticals Inc. (the " Registrant ") will be updating its company overview presentation on its website, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Company Presentation 104 Cover Page Interactive Data File (formatted as inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Verrica Pharmaceuticals Inc. Date: January 8, 2024 /s/ P. Terence Kohler Jr. P. Terence Kohler Jr. Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.